💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Cabozantinib

CHEMBL2105717 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
501.5 g/mol
LogP
5.4
Phase
4

A multikinase inhibitor that blocks several receptors including VEGFR, MET, and RET involved in tumor growth and spread. It is used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Side effects include hypertension, diarrhea, hand-foot skin reaction, and liver function abnormalities.

분자량

501.5000 g/mol

LogP

5.40

TPSA

98.80 Ų

리핀스키 5의 법칙

불통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Melanoma Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

작용 기전

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC

                

                

                
                

                    
InChI

                    
InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)

                

                

                

                    
                    

                        
Molecular Formula

                        
C28H24FN3O5

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
회전 가능 결합

                        
8

                    

                    
                    
                    

                        
무거운 원자

                        
37

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
A multikinase inhibitor that blocks several receptors including VEGFR, MET, and RET involved in tumor growth and spread. It is used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Side effects include hypertension, diarrhea, hand-foot skin reaction, and liver function abnormalities.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Cabozantinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2105717.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 25102847.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.